Literature DB >> 8962072

Dominant negative inhibition by fragments of a monomeric enzyme.

J E Michaels1, P Schimmel, K Shiba, W T Miller.   

Abstract

Dominant negative inhibition is most commonly seen when a mutant subunit of a multisubunit protein is coexpressed with the wild-type protein so that assembly of a functional oligomer is impaired. By analogy, it should be possible to interfere with the functional assembly of a monomeric enzyme by interfering with the folding pathway. Experiments in vitro by others suggested that fragments of a monomeric enzyme might be exploited for this purpose. We report here dominant negative inhibition of bacterial cell growth by expression of fragments of a tRNA synthetase. Inhibition is fragment-specific, as not all fragments cause inhibition. An inhibitory fragment characterized in more detail forms a specific complex with the intact enzyme in vivo, leading to enzyme inactivation. This fragment also associated stoichiometrically with the full-length enzyme in vitro after denaturation and refolding, and the resulting complex was catalytically inactive. Inhibition therefore appears to arise from an interruption in the folding pathway of the wild-type enzyme, thus suggesting a new strategy to design dominant negative inhibitors of monomeric enzymes.

Mesh:

Substances:

Year:  1996        PMID: 8962072      PMCID: PMC26153          DOI: 10.1073/pnas.93.25.14452

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Protein fragments as probes in the study of protein folding mechanisms: differential effects of dihydrofolate reductase fragments on the refolding of the intact protein.

Authors:  J G Hall; C Frieden
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase.

Authors:  S Blond; M Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

Review 3.  Role of diffusion in the folding of the alpha subunit of tryptophan synthase from Escherichia coli.

Authors:  B A Chrunyk; C R Matthews
Journal:  Biochemistry       Date:  1990-02-27       Impact factor: 3.162

4.  Antibody as an immunological probe for studying the refolding of bovine serum albumin. I. The catalysis of reoxidation of reduced bovine serum albumin by glutathione and a disulfide interchange enzyme.

Authors:  J M Teale; D C Benjamin
Journal:  J Biol Chem       Date:  1976-08-10       Impact factor: 5.157

Review 5.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

6.  Evidence for dispensable sequences inserted into a nucleotide fold.

Authors:  R M Starzyk; T A Webster; P Schimmel
Journal:  Science       Date:  1987-09-25       Impact factor: 47.728

7.  Unfolding and refolding of a type kappa immunoglobulin light chain and its variable and constant fragments.

Authors:  M Tsunenaga; Y Goto; Y Kawata; K Hamaguchi
Journal:  Biochemistry       Date:  1987-09-22       Impact factor: 3.162

8.  Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus.

Authors:  A D Friedman; S J Triezenberg; S L McKnight
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

9.  Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.

Authors:  T Unger; J A Mietz; M Scheffner; C L Yee; P M Howley
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

10.  Specific sequence homology and three-dimensional structure of an aminoacyl transfer RNA synthetase.

Authors:  T Webster; H Tsai; M Kula; G A Mackie; P Schimmel
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

View more
  8 in total

1.  Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments.

Authors:  J N Pelletier; F X Campbell-Valois; S W Michnick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

2.  Elevated levels of synthesis of over 20 proteins results after mutation of the Rhizobium leguminosarum exopolysaccharide synthesis gene pssA.

Authors:  N Guerreiro; V N Ksenzenko; M A Djordjevic; T V Ivashina; B G Rolfe
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

3.  A p90(rsk) mutant constitutively interacting with MAP kinase uncouples MAP kinase from p34(cdc2)/cyclin B activation in Xenopus oocytes.

Authors:  A C Gavin; A Ni Ainle; E Chierici; M Jones; A R Nebreda
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

4.  Interaction of infectious spleen and kidney necrosis virus ORF119L with PINCH leads to dominant-negative inhibition of integrin-linked kinase and cardiovascular defects in zebrafish.

Authors:  Ji-Min Yuan; Bai-Liang He; Lu-Yun Yang; Chang-Jun Guo; Shao-Ping Weng; Shengwen Calvin Li; Jian-Guo He
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

5.  Mapping functional regions of essential bacterial proteins with dominant-negative protein fragments.

Authors:  Andrew Savinov; Andres Fernandez; Stanley Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-24       Impact factor: 12.779

6.  Characterization of a folding intermediate from HIV-1 ribonuclease H.

Authors:  G Kern; T Handel; S Marqusee
Journal:  Protein Sci       Date:  1998-10       Impact factor: 6.725

7.  High-throughput identification of dominant negative polypeptides in yeast.

Authors:  Michael W Dorrity; Christine Queitsch; Stanley Fields
Journal:  Nat Methods       Date:  2019-04-08       Impact factor: 28.547

8.  Splice variants of the endonucleases XPF and XPG contain residual DNA repair capabilities and could be a valuable tool for personalized medicine.

Authors:  Janin Lehmann; Steffen Schubert; Christina Seebode; Antje Apel; Andreas Ohlenbusch; Steffen Emmert
Journal:  Oncotarget       Date:  2017-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.